Pfizer Inc. (PFE)
Pfizer's Q2 Focus: Core Products And New Ventures
Analysts predict Pfizer's Q2 2024 revenue to be around $13 billion. The EPS estimate for Q2 2024 is $0.22, reflecting challenges from decreased COVID-19 product demand. Investors are closely watching the performance of Pfizer's core products, particularly in oncology and vaccines, excluding COVID-19 products.
Seeking Clues to Pfizer (PFE) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Pfizer (PFE) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Pfizer (PFE) Gains 7.3% in 2024 on its Weigh-Loss Drug Pipeline
Shares of Pfizer (PFE) are up 7.3% in 2024, based on its weight-loss drug program. The stock must be watched for further developments.
Beware, Wegovy -- Pfizer Is Working on a Competitor
Pfizer's weight loss candidate is moving closer to pivotal studies. This product had encouraging results in phase 2 studies.
UK regulator authorises Pfizer-BioNTech shot for JN.1 COVID variant
Britain's health regulator said on Wednesday it has authorised Pfizer and BioNTech's updated COVID-19 vaccine that targets the JN.1 subvariant of the coronavirus for use in infants, children and adults.
Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study
Sangamo Therapeutics Inc SGMO, which developed a treatment in collaboration with Pfizer Inc PFE, received a boost to its stock price after struggling with liquidity issues.
Pfizer (PFE) Q2 Earnings Coming Up: What Should Investors Do?
Pfizer ( PFE) will report its second-quarter 2024 earnings on Jul 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.22 billion and 45 cents per share, respectively.
This Promising Weight Loss Drug Candidate Could Be a Huge Growth Catalyst for Pfizer
Pfizer is developing danuglipron -- a once-daily weight loss drug. In studies of a twice-daily version, some trial participants lost more than 10% of their body weight.
Pfizer's gene therapy for rare genetic bleeding disorder succeeds in late-stage trial
Pfizer said its experimental gene therapy for a rare genetic blood-clotting disorder succeeded in a large late-stage trial, paving the way for a potential approval. The hemophilia A treatment could become the company's second gene therapy to enter the U.S. market after Beqvez, which was cleared in April for hemophilia B.
Pfizer's hemophilia A gene therapy found superior to current treatment in late-stage trial
Pfizer said on Wednesday that its gene therapy for hemophilia A significantly cut the number of annual bleeding episodes in patients with the rare disorder in a late-stage study and performed better than the current standard treatment.
Earnings Preview: Pfizer (PFE) Q2 Earnings Expected to Decline
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche
Pfizer and Roche don't have any anti-obesity medicines marketed yet. Both are trying to change that as fast as possible.
